Denali Therapeutics Inc. (DNLI) shares ended the last trading session 9.7% higher at $23.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.2% loss over the past four weeks.Denali is developing a broad portfolio of product candidates engineered to cross the blood-brain barrie for the treatment of neurodegenerative and lysosomal storage diseases. The recent upward price trajectory can be attributed to positive up ...